Comprehensive Health Profile And Quality Of Life Assessment In Women Using The Etonogestrel Subdermal Implant: A Cross-Sectional Study

This dataset contains anonymized data from a single-center, hospital-based cross-sectional study with paired hormonal measurements in 200 women using the etonogestrel (ENG) 68 mg subdermal implant (Nexplanon) at approximately 12 months after insertion. Data were collected at the Department of Obstetrics and Gynecology, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye. Associated publication: Kececi Oguzhanoglu M, Karacabey Cakmak S, Sevim Pehlivan K, Gungor E, Oguzhanoglu K, Cetin A. Comprehensive health profile and quality of life assessment in women using the etonogestrel subdermal implant: a cross-sectional study. The European Journal of Contraception & Reproductive Health Care. 2026 [submitted]. Variables: The dataset includes paired serum measurements of gonadotropins (FSH, LH), estradiol, anti-Mullerian hormone (AMH), and a full androgen panel (total testosterone, sex hormone-binding globulin, free testosterone, and dehydroepiandrosterone sulfate) obtained at pre-insertion (from electronic medical records) and at the 12-month study visit. The dataset also includes anthropometric variables (age, height, paired weight and BMI), parity, education, employment status, menstrual pattern before and at 12 months, a multiple-response symptom checklist covering the first 6 months after insertion and the current visit, and validated patient-reported instruments: the Patient Health Questionnaire-9 (PHQ-9), a 4-item short form of the Generalized Anxiety Disorder scale (GAD-7), the Female Sexual Function Index (FSFI) six-item composite, and the EQ-5D-5L descriptive system with a 0–100 visual analog scale. Structure: The dataset consists of a single Excel worksheet with 200 rows (one per participant) and 54 columns. Column headers are in English and follow a snake_case naming convention. Paired hormonal parameters are indicated with "_pre" (pre-insertion) and "_post" (12-month visit) suffixes, and units are embedded in the variable names. Ethics and consent: The study was approved by the Institutional Ethics Committee of Haseki Training and Research Hospital (approval no. 44-2026, date 04.03.2026) and was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent. Anonymization: Names and surnames have been replaced with sequential participant codes (P001–P200); exact implant insertion dates have been transformed into approximate "months since insertion" values; no hospital record numbers, national identity numbers, or contact information are included. Access: This dataset is deposited under Restricted Access in accordance with the scope of the institutional ethics approval. Qualified researchers may request access for purposes compatible with the original participant consent, including reproducibility analyses, meta-analyses on the etonogestrel implant, and methodological re-analyses. Commercial re-use is not permitted.